While the FDA mulls whether to approve Protagonist Therapeutics’ hematology asset, the biopharma is thinking it will pocket $400 million rather than split profits with Takeda.
- Home |
- Protagonist plans to pocket $400M from Takeda rather than split US rusfertide profits
Protagonist plans to pocket $400M from Takeda rather than split US rusfertide profits
- February 26, 2026
Recent Posts
- Oil jumps 5% as Hormuz tanker attacks escalate, US Gulf hurricane shuts in production
- Crescent Energy to acquire Eagle Ford assets from Devon for $4.2 billion
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
